Active Not Recruiting PHASE1/PHASE2 INTERVENTIONAL 5-arm NCT03294083

A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma

A Phase 1b/2a Dose-escalation and Safety/Efficacy Evaluation Study of Pexa-Vec (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) in Combination With Cemiplimab (REGN2810; Anti-PD-1) in Patients With Metastatic or Unresectable Renal Cell Carcinoma (RCC)

Sponsor: Regeneron Pharmaceuticals

Conditions Renal Cell Carcinoma

Interventions Cemiplimab Pexastimogene Devacirepvec (Pexa-Vec)

Updated 20 times since 2017 Last updated: Oct 26, 2022 Started: Jun 7, 2018 Primary completion: Aug 31, 2023 Completion: Nov 30, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03294083, this PHASE1/PHASE2 trial focuses on Renal Cell Carcinoma and remains ongoing. Sponsored by Regeneron Pharmaceuticals, it has been updated 20 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

20 versions recorded

Sep 2025 — Present [monthly]

Active Not Recruiting PHASE1/PHASE2
Sep 2024 — Sep 2025 [monthly]

Active Not Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Nov 2022 — Jul 2024 [monthly]

Active Not Recruiting PHASE1_PHASE2
Sep 2022 — Nov 2022 [monthly]

Active Not Recruiting PHASE1_PHASE2

Status: Recruiting → Active Not Recruiting

▶ Show 15 earlier versions

Oct 2021 — Sep 2022 [monthly]

Recruiting PHASE1_PHASE2
Feb 2021 — Oct 2021 [monthly]

Recruiting PHASE1_PHASE2

Phase: PHASE1 → PHASE1_PHASE2
Jan 2021 — Feb 2021 [monthly]

Recruiting PHASE1
Aug 2020 — Jan 2021 [monthly]

Recruiting PHASE1
Apr 2020 — Aug 2020 [monthly]

Recruiting PHASE1
Jun 2019 — Apr 2020 [monthly]

Recruiting PHASE1
Mar 2019 — Jun 2019 [monthly]

Recruiting PHASE1
Feb 2019 — Mar 2019 [monthly]

Recruiting PHASE1
Jan 2019 — Feb 2019 [monthly]

Recruiting PHASE1
Oct 2018 — Jan 2019 [monthly]

Recruiting PHASE1
Sep 2018 — Oct 2018 [monthly]

Recruiting PHASE1
Aug 2018 — Sep 2018 [monthly]

Recruiting PHASE1
Jun 2018 — Aug 2018 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
May 2018 — Jun 2018 [monthly]

Not Yet Recruiting PHASE1
Oct 2017 — May 2018 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Regeneron Pharmaceuticals
SillaJen, Inc.

Data source: SillaJen, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bedford Park, Australia , Columbus, United States , Daegu, South Korea , Daejeon, South Korea , Gwangju, South Korea , Incheon, South Korea , Irvine, United States , Miami, United States , Pusan, South Korea , Seongnam, South Korea and 6 more locations